India’s DCGI, U.S. FDA Collaborate On Drug Rules
This article was originally published in PharmAsia News
Executive Summary
The Drug Controller General of India and its U.S. counterpart, FDA, are in discussions expected to lead to a stronger regulatory agency. The talks cover improved monitoring of drugs, regulations covering medical devices and rules governing clinical practices and biologics. The DCGI also has plans to inspect plants in other countries, such as China, where raw materials are made for export to Indian drug makers. A DCGI team visited the FDA's offices last month and the U.S. agency plans to open offices in three Indian cities. (Click here for more